Volume 25 Issue 1
Nov.  2019
Turn off MathJax
Article Contents

JIANG Feng, LI Qing, HU Cheng, ZHANG Rong, WANG Cong Rong, YU Wei Hui, LU Jing Yi, TANG Shan Shan, BAO Yu Qian, XIANG Kun San, JIA Wei Ping. Association of a SLC30A8 Genetic Variant with Monotherapy of Repaglinide and Rosiglitazone Effect in Newly Diagnosed Type 2 Diabetes Patients in China[J]. Biomedical and Environmental Sciences, 2012, 25(1): 23-29. doi: 10.3967/0895-3988.2012.01.004
Citation: JIANG Feng, LI Qing, HU Cheng, ZHANG Rong, WANG Cong Rong, YU Wei Hui, LU Jing Yi, TANG Shan Shan, BAO Yu Qian, XIANG Kun San, JIA Wei Ping. Association of a SLC30A8 Genetic Variant with Monotherapy of Repaglinide and Rosiglitazone Effect in Newly Diagnosed Type 2 Diabetes Patients in China[J]. Biomedical and Environmental Sciences, 2012, 25(1): 23-29. doi: 10.3967/0895-3988.2012.01.004

Association of a SLC30A8 Genetic Variant with Monotherapy of Repaglinide and Rosiglitazone Effect in Newly Diagnosed Type 2 Diabetes Patients in China

doi: 10.3967/0895-3988.2012.01.004
Funds:  This work was funded by National 863 Program(2006AA02A409)%major program of Shanghai Municipality for Basic Research(08dj1400601)%"Chen Guang" Project(09CG07)
  • Objective To investigate a potential relationship between Solute carrier family 30 (zinc transporter)member 8 (SLC30A8) rs13266634 variant and efficacy of rosiglitazone or repaglinide in treating newly diagnosed Chinese type 2 diabetes patients.Methods A total of 209 diabetic patients without any antihyperglycemic history were recruited and treated with repaglinide or rosiglitazone randomly for 48 weeks (104 and 105 patients,respectively).Anthropometric measurements and clinical laboratory tests were carried out before and after the treatment.An non-synonymous variant rs13266634 was genotyped by matrix-assisted laser desorption ionization-time of flight mass spectroscopy.Results Ninety-one patients in repaglinide group and ninety-three patients in rosiglitazone group completed the study.A value of homeostasis model assessment of beta cell function (HOMA-B) and A value of fasting proinsulin levels were statistically significant between three genotype groups (P=0.0149and 0.0246,respectively) after rosiglitazone treatment.However,no genotype association was observed in the repaglinide or rosiglitazone group with other parameters.Conclusion The SLC30A8 variant was associated with the efficacy of insulin sensitizer monotherapy on insulin secretion in patients with newly diagnosed type 2 diabetes mellitus in Shanghai,China.
  • 加载中
  • 加载中
通讯作者: 陈斌, bchen63@163.com
  • 1. 

    沈阳化工大学材料科学与工程学院 沈阳 110142

  1. 本站搜索
  2. 百度学术搜索
  3. 万方数据库搜索
  4. CNKI搜索

Article Metrics

Article views(942) PDF downloads(50) Cited by()

Proportional views
Related

Association of a SLC30A8 Genetic Variant with Monotherapy of Repaglinide and Rosiglitazone Effect in Newly Diagnosed Type 2 Diabetes Patients in China

doi: 10.3967/0895-3988.2012.01.004
Funds:  This work was funded by National 863 Program(2006AA02A409)%major program of Shanghai Municipality for Basic Research(08dj1400601)%"Chen Guang" Project(09CG07)

Abstract: Objective To investigate a potential relationship between Solute carrier family 30 (zinc transporter)member 8 (SLC30A8) rs13266634 variant and efficacy of rosiglitazone or repaglinide in treating newly diagnosed Chinese type 2 diabetes patients.Methods A total of 209 diabetic patients without any antihyperglycemic history were recruited and treated with repaglinide or rosiglitazone randomly for 48 weeks (104 and 105 patients,respectively).Anthropometric measurements and clinical laboratory tests were carried out before and after the treatment.An non-synonymous variant rs13266634 was genotyped by matrix-assisted laser desorption ionization-time of flight mass spectroscopy.Results Ninety-one patients in repaglinide group and ninety-three patients in rosiglitazone group completed the study.A value of homeostasis model assessment of beta cell function (HOMA-B) and A value of fasting proinsulin levels were statistically significant between three genotype groups (P=0.0149and 0.0246,respectively) after rosiglitazone treatment.However,no genotype association was observed in the repaglinide or rosiglitazone group with other parameters.Conclusion The SLC30A8 variant was associated with the efficacy of insulin sensitizer monotherapy on insulin secretion in patients with newly diagnosed type 2 diabetes mellitus in Shanghai,China.

JIANG Feng, LI Qing, HU Cheng, ZHANG Rong, WANG Cong Rong, YU Wei Hui, LU Jing Yi, TANG Shan Shan, BAO Yu Qian, XIANG Kun San, JIA Wei Ping. Association of a SLC30A8 Genetic Variant with Monotherapy of Repaglinide and Rosiglitazone Effect in Newly Diagnosed Type 2 Diabetes Patients in China[J]. Biomedical and Environmental Sciences, 2012, 25(1): 23-29. doi: 10.3967/0895-3988.2012.01.004
Citation: JIANG Feng, LI Qing, HU Cheng, ZHANG Rong, WANG Cong Rong, YU Wei Hui, LU Jing Yi, TANG Shan Shan, BAO Yu Qian, XIANG Kun San, JIA Wei Ping. Association of a SLC30A8 Genetic Variant with Monotherapy of Repaglinide and Rosiglitazone Effect in Newly Diagnosed Type 2 Diabetes Patients in China[J]. Biomedical and Environmental Sciences, 2012, 25(1): 23-29. doi: 10.3967/0895-3988.2012.01.004

Catalog

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return